FDA says KM Pharmaceutical refused to provide drug records and placed all its drugs on import alert.
What happened
FDA reviewed import records showing multiple shipments of drug products into the U.S. that declared KM Pharmaceutical as the manufacturer. FDA sent records requests under section 704(a)(4) on March 3 and March 16, 2023, called the registered U.S. agent on April 12, and sent a follow-up written request on April 17. The firm did not respond or provide the requested records, and FDA placed all drugs and drug products made by the firm on Import Alert 66-79 on June 7, 2023.
What FDA found
The firm refused to permit access to or copying of records required by FDA.
section 301(e) of the FD&C Act, 21 U.S.C. 331(e)The firm did not answer FDA's section 704(a)(4) request for records and other information about its drug manufacturing.
section 704(a)(4) of the FD&C Act, 21 U.S.C. 374(a)(4)
What FDA wants
Respond in writing within 15 working days to CDER, identifying FEI #3010164172 and ATTN Matthew R. Dionne; the firm may provide information for FDA to consider or request an FDA inspection.
Who should pay attention
- brands that buy OTC drugs or hand sanitizer from KM Pharmaceutical
- U.S. importers and distributors of KM-made drug products
- quality teams checking suppliers for DEG/EG risks in high-risk ingredients
This is a summary. Read the original letter on fda.gov.